Insmed Inc. (INSM) announced Monday morning that the FDA has lifted the clinical hold previously placed on ARIKACE in Cystic Fibrosis patients with Pseudomonas lung infections.
Insmed gapped up sharply Monday and has continued to rise, with volume at over a 3-month high. The stock is now up 1.28 at $3.98 and has set over a month and a half high. Insmed has also re-crossed its 50-day moving average.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.